Literature DB >> 1417067

Cutaneous drug reactions. An attempt to quantitative estimation.

G Swanbeck1, E Dahlberg.   

Abstract

The drugs taken by patients with suspected cutaneous drug reactions (CDR) were recorded during a 4-year period at Sahlgren Hospital in Gotenburg in a prospective study. A total of 440 patients were included. By dividing the frequency of occurrence of the recorded drugs by the number of sold defined daily doses (SDDD) for the city during the same period of time, figures for the CDR risk for different drugs corrected for frequency of use were obtained. The risk of CDR seemed to be highest for gold compounds, trimethoprim with and without sulphonamides, cephalosporins and penicillins. The most common types of CDR were macular and mucalopapular eruptions, followed by urticaria and cutaneous vasculitis. The results correlate well with those of the Boston Collaborative Drug Surveillance Program.

Entities:  

Mesh:

Year:  1992        PMID: 1417067     DOI: 10.1007/bf00375796

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  2 in total

1.  Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  K A Arndt; H Jick
Journal:  JAMA       Date:  1976-03-01       Impact factor: 56.272

2.  Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982.

Authors:  M Bigby; S Jick; H Jick; K Arndt
Journal:  JAMA       Date:  1986-12-26       Impact factor: 56.272

  2 in total
  3 in total

Review 1.  Diagnosis and treatment of allergic skin disorders in the elderly.

Authors:  S T Nedorost; S R Stevens
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Severe drug eruptions revisited.

Authors:  Sebastien Calbo
Journal:  Immunol Res       Date:  2012-09       Impact factor: 4.505

3.  A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.

Authors:  Matthew Dryden; Yingyuan Zhang; David Wilson; Joseph P Iaconis; Jesus Gonzalez
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.